Tuesday, October 4, 2022

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Preparing for Ketamine Tech FDA Pre-Investigational New Drug Package

 Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is collaborating with Premier Consulting to prepare a pre-investigational new drug (“IND”) package and meeting request with the United States Food and Drug Administration (FDA) for SPC-26, the company’s novel topical formulation of ketamine for the treatment of fibromyalgia. The company is planning to pursue a 505(b)(2) regulatory pathway for novel topical formulation of ketamine. According to the company, Premier Consulting will assist with the development of SILO’s nonclinical, clinical, clinical pharmacology, and biopharmaceutics strategy and program to be proposed to the FDA. Silo is planning to submit the pre-IND meeting request for collaborative discussions with the FDA in anticipation of the filing a clinical IND package. “We are confident that our highly constructive preclinical work on SP-26 will offer strong support for our pre-IND package as we seek to advance our time-released ketamine delivery system into the clinic,” said Silo Pharma CEO Eric Weisblum in the press release. “We intend to pursue the 505(b)(2) regulatory pathway and have engaged Premier Consulting as a true strategic partner to pave the way for productive discussions and alignment with the FDA.”

To view the full press release, visit https://ibn.fm/Jq2I1

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html